Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

Keyphrases

• Chemotherapy 100%
• Carbohydrate Antigen 19-9 (CA19-9) 100%
• Bile Duct Cancer 100%
• Validation Cohort 20%
• Hazard Ratio 10%
• Consecutive Patients 10%
• Treatment Effect 10%
• University Hospital 10%
• Multivariate Analysis 10%
• Treatment Monitoring 10%
• Predictive Value 10%
• Bilirubin 10%
• Carbohydrates 10%
• Phase II Trial 10%
• Performance Status 10%
• Pancreatic Cancer 10%
• Survival Prediction 10%
• Radiological Response 10%
• Response to Chemotherapy 10%
• Associated Antigen 10%
• Multivariate Cox Regression Analysis 10%
• Biomarkers of Response 10%
• Validation Set 10%
• Serum CA19-9 10%
• Response Performance 10%

Medicine and Dentistry

• Bile Duct Cancer 100%
• CA19-9 100%
• Biological Marker 20%
• Disease 10%
• Malignant Neoplasm 10%
• Multivariate Analysis 10%
• Hazard Ratio 10%
• Proportional Hazards Model 10%
• Treatment Effect 10%
• Pancreas Cancer 10%
• Bilirubin 10%

Biochemistry, Genetics and Molecular Biology

• CA19-9 100%
• Multivariate Analysis 10%
• Bilirubin 10%